Cardio Diagnostics CEO Outlines Growth Strategy and India Expansion Amid Medicare Progress

Cardio Diagnostics Holdings (NASDAQ: CDIO) is advancing its mission to improve cardiovascular disease prevention and early detection through precision medicine, as outlined by CEO and Co-Founder Dr. Meesha Dogan in a recent interview on The BioMedWire Podcast. The company leverages epigenetics, genetics, and artificial intelligence to develop clinical tests that make cardiovascular care more personalized and accessible.

During the podcast, Dogan highlighted Cardio Diagnostics’ strategic expansion into India through partnerships with Aimil Ltd. and Dr. Lal PathLabs, a move that could significantly broaden the company's reach in one of the world's most populous countries. This expansion is part of the company's broader growth strategy to address the global burden of cardiovascular disease, which remains a leading cause of death worldwide.

Dogan also provided an update on the company's progress through the Medicare reimbursement process. According to the CEO, the CPT coding and payment steps have been completed, while coverage determination is still underway. This milestone is critical for the company as it seeks to ensure that its tests are accessible to Medicare beneficiaries, potentially opening up a large patient population.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that aims to make prevention, detection, and management of cardiovascular disease more precise. The company's proprietary AI-driven Integrated Genetic-Epigenetic Engine forms the core technology for its clinical tests, positioning it to become a leading medtech company in the cardiovascular space.

The interview on BioMedWire underscores the company's commitment to leveraging innovative technology to tackle cardiovascular disease. With the India expansion and progress in Medicare reimbursement, Cardio Diagnostics is taking concrete steps to scale its impact and bring its precision medicine solutions to a wider audience.

For more information on Cardio Diagnostics, visit the company's newsroom at https://ibn.fm/CDIO.